A Phase 1, Open-label, Single Ascending Dose, Parallel Arm Trial to Determine the Pharmacokinetics, Safety, and Tolerability of Aripiprazole 2 Month Intramuscular Depot Administered Gluteally in Adult Subjects With Schizophrenia
Phase of Trial: Phase I
Latest Information Update: 18 Jun 2018
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 11 Jun 2018 Status changed from active, no longer recruiting to completed.
- 28 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Jul 2017 Status changed from not yet recruiting to recruiting.